Last update 22 Apr 2026

HBT-708

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
708, HBT 708, HBT708
+ [2]
Target
PD-1 x TGF-β
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors)
Therapeutic Areas
NeoplasmsDigestive System Disorders
Active Indication
Advanced Malignant Solid NeoplasmGastrooesophageal junction cancer
Inactive Indication-
Originator Organization
Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd.
Active Organization
Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.
Inactive Organization-
License Organization
Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd.
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with HBT-708
NCT06993870
/ RecruitingPhase 1
A Phase I Study to Evaluate the Safety, Tolerability, and Initial Efficacy of HBT-708 Monotherapy for Patients With Advanced Solid Tumors
100 Clinical Results associated with HBT-708
Login to view more data
100 Translational Medicine associated with HBT-708
Login to view more data
100 Patents (Medical) associated with HBT-708
Login to view more data
100 Deals associated with HBT-708
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
China
Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd.
09 Jun 2025
Gastrooesophageal junction cancerIND Approval
China
Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.
02 Feb 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free